{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:02:22Z","timestamp":1788436942610,"version":"build-2803163510"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0051449","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T19:25:25Z","timestamp":1354735525000},"page":"e51449","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["Synergistic Effects of Combined Wnt\/KRAS Inhibition in Colorectal Cancer Cells"],"prefix":"10.1371","volume":"7","author":[{"given":"Luca","family":"Mologni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Brussolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ceccon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"H Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"ref2","first-page":"392","article-title":"Use of erlotinib or gefitinib as initial therapy in advanced NSCLC","volume":"24","author":"GR Oxnard","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: setting the stage for molecularly targeted cancer therapy","volume":"21","author":"SV Sharma","year":"2007","journal-title":"Genes Dev"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1158\/1078-0432.CCR-04-0031","article-title":"Different genetic features associated with colon and rectal carcinogenesis","volume":"10","author":"M Frattini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1056\/NEJMra0804588","article-title":"Molecular origins of cancer: Molecular basis of colorectal cancer","volume":"361","author":"SD Markowitz","year":"2009","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscapes of human breast and colorectal cancers","volume":"318","author":"LD Wood","year":"2007","journal-title":"Science"},{"key":"ref7","unstructured":"Kucherlapati R (2012) Integrative analysis examples from TCGA tumor projects. AACR Annual Meeting."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e27136","DOI":"10.1371\/journal.pone.0027136","article-title":"The temporal order of genetic and pathway alterations in tumorigenesis","volume":"6","author":"M Gerstung","year":"2011","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0092-8674(02)01014-0","article-title":"The beta-catenin\/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells","volume":"111","author":"M van de Wetering","year":"2002","journal-title":"Cell"},{"key":"ref10","first-page":"1291","article-title":"Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells","volume":"9","author":"UN Verma","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref11","first-page":"3465","article-title":"Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation","volume":"61","author":"JM Mariadason","year":"2001","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/bjc.1992.416","article-title":"Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation","volume":"66","author":"N Fabien","year":"1992","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.1133427","article-title":"The consensus coding sequences of human breast and colorectal cancers","volume":"314","author":"T Sjoblom","year":"2006","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e24114","DOI":"10.1371\/journal.pone.0024114","article-title":"Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients","volume":"6","author":"P Vasovcak","year":"2011","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, <etal>et al<\/etal>.. (2008) RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and\/or RASSF1A. Neoplasia 10: 680-686, 682 p following 686.","DOI":"10.1593\/neo.08312"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Network The Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1053\/j.gastro.2006.08.011","article-title":"APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression","volume":"131","author":"KP Janssen","year":"2006","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"14122","DOI":"10.1073\/pnas.0604130103","article-title":"Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo","volume":"103","author":"OJ Sansom","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1158\/0008-5472.CAN-10-1108","article-title":"Colorectal Tumors Are Effectively Eradicated by Combined Inhibition of {beta}-Catenin, KRAS, and the Oncogenic Transcription Factor ITF2","volume":"70","author":"L Mologni","year":"2010","journal-title":"Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"K Sukhdeo","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1593\/neo.91972","article-title":"Small molecule inhibitors of Wnt\/beta-catenin\/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo","volume":"12","author":"RK Gandhirajan","year":"2010","journal-title":"Neoplasia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1535-6108(03)00334-9","article-title":"Small-molecule antagonists of the oncogenic Tcf\/beta-catenin protein complex","volume":"5","author":"M Lepourcelet","year":"2004","journal-title":"Cancer Cell"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1210\/jc.2008-0247","article-title":"The T cell factor\/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells","volume":"93","author":"M Doghman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.00207-08","article-title":"Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model","volume":"52","author":"AS Downey","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nchembio.453","article-title":"Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha","volume":"6","author":"CA Thorne","year":"2010","journal-title":"Nat Chem Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jm00008a004","article-title":"Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth","volume":"38","author":"D Marciano","year":"1995","journal-title":"J Med Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","article-title":"Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice","volume":"61","author":"R Haklai","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"A Zundelevich","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","article-title":"The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer","volume":"439","author":"B Rotblat","year":"2008","journal-title":"Methods Enzymol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1073\/pnas.0501535102","article-title":"G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway","volume":"102","author":"M Yang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1073\/pnas.94.19.10330","article-title":"Beta-catenin mutations in cell lines established from human colorectal cancers","volume":"94","author":"M Ilyas","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/hmg\/ddn338","article-title":"Beta-catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours","volume":"18","author":"EM Kohler","year":"2009","journal-title":"Hum Mol Genet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1158\/0008-5472.CAN-05-4108","article-title":"KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand","volume":"66","author":"N Smakman","year":"2006","journal-title":"Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1038\/sj.onc.1204611","article-title":"Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines","volume":"20","author":"J Gayet","year":"2001","journal-title":"Oncogene"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/0008-5472.CAN-10-0192","article-title":"Genomic and biological characterization of exon 4 KRAS mutations in human cancer","volume":"70","author":"M Janakiraman","year":"2010","journal-title":"Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00313020801911512","article-title":"Detection of BRAF V600E mutation by pyrosequencing","volume":"40","author":"YH Tan","year":"2008","journal-title":"Pathology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/ijc.24158","article-title":"Valproic acid enhances bosutinib cytotoxicity in colon cancer cells","volume":"124","author":"L Mologni","year":"2009","journal-title":"Int J Cancer"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid","volume":"1452","author":"G Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","article-title":"A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice","volume":"18","author":"B Weisz","year":"1999","journal-title":"Oncogene"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1535-7163.MCT-10-0262","article-title":"Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas","volume":"9","author":"R Levy","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1126\/science.281.5382.1509","article-title":"Identification of c-MYC as a target of the APC pathway","volume":"281","author":"TC He","year":"1998","journal-title":"Science"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(00)80308-1","article-title":"Ras enhances Myc protein stability","volume":"3","author":"R Sears","year":"1999","journal-title":"Mol Cell"},{"key":"ref44","first-page":"8664","article-title":"Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer","volume":"61","author":"T Zhang","year":"2001","journal-title":"Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"19273","DOI":"10.1074\/jbc.M610350200","article-title":"Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer","volume":"282","author":"R Kaneko","year":"2007","journal-title":"J Biol Chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1535-7163.MCT-06-0560","article-title":"Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells","volume":"6","author":"AV Sarthy","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt1976196802","article-title":"Absorption of pyrvinium pamoate","volume":"19","author":"TC Smith","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1349-7006.2004.tb03330.x","article-title":"Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation","volume":"95","author":"H Esumi","year":"2004","journal-title":"Cancer Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e3951","DOI":"10.1371\/journal.pone.0003951","article-title":"Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy","volume":"3","author":"DH Yu","year":"2008","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1073\/pnas.1010978107","article-title":"Accumulation of driver and passenger mutations during tumor progression","volume":"107","author":"I Bozic","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00439-011-1010-0","article-title":"Somatic variation and cancer: therapies lost in the mix","volume":"130","author":"AV Biankin","year":"2011","journal-title":"Hum Genet"},{"key":"ref52","first-page":"127","article-title":"K-ras as a target for cancer therapy","volume":"1756","author":"BB Friday","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"ref53","first-page":"12","article-title":"Inhibition of MEK and PI3K\/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas","volume":"2012","author":"G Migliardi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1172\/JCI57909","article-title":"Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers","volume":"121","author":"H Ebi","year":"2011","journal-title":"J Clin Invest"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/ijc.24604","article-title":"Intrinsic resistance to the MEK1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1\/2 signalling and\/or strong PI3K signalling in colorectal cancer cell lines","volume":"125","author":"K Balmanno","year":"2009","journal-title":"Int J Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2009.03.017","article-title":"Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells","volume":"137","author":"C Scholl","year":"2009","journal-title":"Cell"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cell.2011.12.033","article-title":"TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers","volume":"148","author":"A Singh","year":"2012","journal-title":"Cell"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","article-title":"A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene","volume":"137","author":"J Luo","year":"2009","journal-title":"Cell"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0962-8924(03)00152-1","article-title":"Ral-GTPases: approaching their 15 minutes of fame","volume":"13","author":"LA Feig","year":"2003","journal-title":"Trends Cell Biol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"14335","DOI":"10.1074\/jbc.M703811200","article-title":"Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells","volume":"283","author":"S Misra","year":"2008","journal-title":"J Biol Chem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1742-4658.2011.08071.x","article-title":"Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy","volume":"278","journal-title":"FEBS J"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1128\/MCB.16.12.6654","article-title":"Protective role of p21(Waf1\/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells","volume":"16","author":"M Gorospe","year":"1996","journal-title":"Mol Cell Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1128\/MCB.16.4.1335","article-title":"The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells","volume":"16","author":"W Poluha","year":"1996","journal-title":"Mol Cell Biol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0051449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:43:44Z","timestamp":1539996224000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0051449"}},"subtitle":[],"editor":[{"given":"Neil A.","family":"Hotchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0051449","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}